Fresenius SE & Co. KGaA operates as a diverse healthcare enterprise, supplying a comprehensive array of products and services primarily focused on dialysis, hospital management, and outpatient medical care. Its activities are structured across four main divisions: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care division is dedicated to individuals living with chronic kidney failure, offering essential items like dialyzers, hemodialysis machines, and related disposable supplies, alongside various dialysis-specific services. Fresenius Kabi concentrates on the therapeutic treatment and care of ill patients. Its extensive product range includes intravenous pharmaceuticals, such as generic drugs for oncology, anesthetics, pain relief, anti-infectives, and critical care. Additionally, it provides parenteral and enteral nutritional products, infusion solutions, and blood volume expanders for infusion therapy. The segment also develops biosimilars—biological medicines for autoimmune and cancer conditions—and manufactures medical devices and disposables crucial for administering IV generics, infusion treatments, and clinical nutrition. Transfusion products for blood component collection and corporeal therapies are also part of its offerings. Fresenius Helios manages significant healthcare operations, encompassing 90 hospitals, approximately 130 outpatient clinics, and 6 prevention centers throughout Germany. In Spain, its presence includes 49 hospitals, 88 outpatient clinics, and around 300 risk prevention centers. This segment also delivers fertility treatment services through 33 clinics and an additional 39 sites located across 10 countries on three continents. Finally, the Fresenius Vamed division specializes in project management and service delivery for hospitals and other healthcare facilities. Its offerings span project development, meticulous planning, and turnkey construction solutions. Furthermore, it provides ongoing maintenance, technical oversight, and operational management services. The company, initially known as Fresenius SE, officially changed its name to Fresenius SE & Co. KGaA in January 2011. Founded in 1912, Fresenius SE & Co. KGaA maintains its corporate headquarters in Bad Homburg vor der Höhe, Germany.
The current price of FSNUF is $60.17 USD — it has increased by +28.4% in the past 24 hours. Watch Fresenius stock price performance more closely on the chart.
What is Fresenius stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Fresenius stocks are traded under the ticker FSNUF.
Is Fresenius stock price growing?▼
FSNUF stock has risen by +5.56% compared to the previous week, the month change is a +5.56% rise, over the last year Fresenius has showed a +8.94% increase.
What is Fresenius market cap?▼
Today Fresenius has the market capitalization of 33.89B
When is the next Fresenius earnings date?▼
Fresenius is going to release the next earnings report on February 24, 2027.
What were Fresenius earnings last quarter?▼
FSNUF earnings for the last quarter are 0.82 USD per share, whereas the estimation was 0.88 USD resulting in a -7.14% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Fresenius revenue for the last year?▼
Fresenius revenue for the last year amounts to 26.35B USD.
What is Fresenius net income for the last year?▼
FSNUF net income for the last year is 1.44B USD.
Does Fresenius pay dividends?▼
Yes, FSNUF dividends are paid annual. The last dividend per share was 1.22 . As of today, Dividend Yield (FWD)% is 2.03%.
How many employees does Fresenius have?▼
As of November 13, 2026, the company has 178,394 employees.
In which sector is Fresenius located?▼
Fresenius operates in the Health & Wellness sector.
When did Fresenius complete a stock split?▼
The last stock split for Fresenius was on August 5, 2014 with a ratio of 1.5:1.
Where is Fresenius headquartered?▼
Fresenius is headquartered in Bad Homburg vor der Höhe, Germany.